2207 BRAIN Biotech
2207 BRAIN Biotech

BRAIN Biotech AG reports final half-year figures for fiscal year 2024/25

BRAIN Biotech AG, a leading provider of specialty enzymes and innovative biological solutions for industry, published its final financial figures for the first six months of fiscal year 2024/25

Published 28 May 2025
Home/ Media & Resources/ BRAIN Biotech AG reports final half-year figures for fiscal year 2024/25
  • BRAINBiocatalysts experienced modest organic growth in the first half of the year
  • BRAINBioIncubator with high basis for comparison in the previous year
  • Strong liquidity maintained at €14.9 million


BRAIN Biotech AG, a leading provider of specialty enzymes and innovative biological solutions for industry, published its final financial figures for the first six months of fiscal year 2024/25. BRAIN Biotech Group generated €25.2 million in revenue during the first half of the fiscal year, which is a 7.2 % decrease from the previous year (€27.2 million). This decline is primarily due to the subdued general economic environment and resulting delays in concluding new contracts for tailor-made solutions projects. Revenue fell by €2.4 million in the second quarter of 2024/25 compared to the previous year's period, dropping from €14.5 million to €12.1 million. This decline is due to the negative economic effects mentioned above and a one-time effect in the previous year: €1.5 million milestone payment for the clinical progress in developing the investigational pharmaceutical drug compound deucrictibant (formerly PHA 121).

Our enzyme-focused product business is performing comparatively better, though still below original expectations at the beginning of the year. We are currently focusing all our efforts on laying the groundwork for accelerated growth in the future and optimising our running costs

Sign up to our newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.